Omarigliptin

Cas No.:	1226781-44-7
Chemical Name:	Omarigliptin
Synonyms:	MK－3012;(2R,3S,5R)-2-(2,5-Difluorophenyl)-5-(2-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)tetrahydro-2H-pyran-3-amine;(2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-methylsulfonyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5-yl)oxan-3-amine;(2R,3S,5R)-2-(2,5-difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3...;MK-3102;Omarigliptin;Omarigliptin (MK3102);(2R,3S,5R)-2-(2,5-difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]-tetrahydro-2H-pyran-3-amine;MK3102;UNII-CVP59Q4JE1;CVP59Q4JE1;(2R,3S,5R)-2-(2,5-Difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine;(2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)tetrahydro-2H-pyran-3-amine;Omarigliptin [USAN:INN];AK170357;Tube;OMARIGLIPTIN;OMARIGLIPTIN;MK-3102Omarigliptin?;MK-3102Omarigliptin?;CHEBI:134735;CHEBI:134735;OMARIGLIPTIN [WHO-DD];OMARIGLIPTIN [WHO-DD];AKOS025289528;AKOS025289528;MKMPWKUAHLTIBJ-ISTRZQFTSA-N;MKMPWKUAHLTIBJ-ISTRZQFTSA-N;NSC-802900;NSC-802900;NSC802900;NSC802900;AC-28992;AC-28992;OMARIGLIPTIN [INN];OMARIGLIPTIN [INN];CHEMBL2105762;CHEMBL2105762;(2R,3S,5R)-2-(2,5-DIFLUOROPHENYL)-5-(2-(METHYLSULFONYL)PYRROLO[3,4-C]PYRAZOL-5(2H,4H,6H)-YL)TETRAHYDRO-2H-PYRAN-3-AMINE;(2R,3S,5R)-2-(2,5-DIFLUOROPHENYL)-5-(2-(METHYLSULFONYL)PYRROLO[3,4-C]PYRAZOL-5(2H,4H,6H)-YL)TETRAHYDRO-2H-PYRAN-3-AMINE;J-690074;J-690074;HY-15981;HY-15981;NS00073001;NS00073001;(2R,3S,5R)-2-(2,5-Difluorophenyl)-5-(2-(methanesulfonyl)-2,6-dihydropyrrolo(3,4- c)pyrazol-5(4H)-yl)oxan-3-amine;(2R,3S,5R)-2-(2,5-Difluorophenyl)-5-(2-(methanesulfonyl)-2,6-dihydropyrrolo(3,4- c)pyrazol-5(4H)-yl)oxan-3-amine;OMARIGLIPTIN [MI];OMARIGLIPTIN [MI];Omarigliptin (JAN/USAN/INN);Omarigliptin (JAN/USAN/INN);2H-Pyran-3-amine, 2-(2,5-difluorophenyl)-5-(2,6-dihydro-2-(methylsulfonyl)pyrrolo(3,4- c)pyrazol-5(4H)-yl)tetrahydro-, (2R,3S,5R)-;2H-Pyran-3-amine, 2-(2,5-difluorophenyl)-5-(2,6-dihydro-2-(methylsulfonyl)pyrrolo(3,4- c)pyrazol-5(4H)-yl)tetrahydro-, (2R,3S,5R)-;s8565;s8565;BDBM50003020;SCHEMBL827590;BDBM50003020;1226781-44-7;SCHEMBL827590;2H-Pyran-3-amine, 2-(2,5-difluorophenyl)-5-[2,6-dihydro-2-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-, (2R,3S,5R)-;1226781-44-7;Omarigliptin (MK-3102);2H-Pyran-3-amine, 2-(2,5-difluorophenyl)-5-[2,6-dihydro-2-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-, (2R,3S,5R)-;EX-A395;Omarigliptin (MK-3102);D10317;EX-A395;GTPL8402;D10317;AM85511;GTPL8402;DTXSID70153678;AM85511;DS-7574;DTXSID70153678;CCG-268634;DS-7574;MFCD22573261;CCG-268634;OMARIGLIPTIN [JAN];MFCD22573261;PB39113;OMARIGLIPTIN [JAN];(2R,3S,5R)-2-(2,5-Difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo(3,4- c)pyrazol-5(4H)-yl)tetrahydro-2H-pyran-3-amine;PB39113;NCGC00480770-01;Q21098979;(2R,3S,5R)-2-(2,5-Difluorophenyl)-5-(2-(m...
SMILES:	S(C([H])([H])[H])(N1C([H])=C2C(C([H])([H])N(C2([H])[H])[C@@]2([H])C([H])([H])O[C@]([H])(C3C([H])=C(C([H])=C([H])C=3F)F)[C@]([H])(C2([H])[H])N([H])[H])=N1)(=O)=O
Formula:	C17H20F2N4O3S
M.Wt:	398.4275
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

Omarigliptin(MK-3102) is a potent, selective and long-acting DPP-4 inhibitor with IC50 of 1.6 nM; highly selective over allproteases tested (IC50 > 67 μM).IC50 value: 1.6 nM [1]Target: DPP-4 inhibitorin vitro: Omarigliptin has weak ion channel activity (IC50 > 30 μM at IKr, Cav1.2, and Nav1.5). An expansive selectivity counterscreen (168 radioligand binding or enzymatic assays) was carried out at MDS Pharma. An IC50 > 10 μM was obtained in all assays. in vivo: When orally administered 1 h prior to dextrose challenge in an oral glucose tolerance test (OGTT), it significantly reduced blood glucose excursion in a dose-dependent manner from 0.01 mg/kg (7% reduction in glucose AUC) to 0.3 mg/kg (51% reduction).